Recent advances in the treatment of hypertension

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 6, 2011, Pages 729-744

  Hering, Dagmara ^a,b   Esler, Murray D ^a,c   Krum, Henry ^c,d   Mahfoud, Felix ^e   Böhm, Michael ^e   Sobotka, Paul A ^f,g   Schlaich, Markus P ^a,c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c ALFRED HOSPITAL   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e SAARLAND UNIVERSITY   (Germany)

^f HENNEPIN COUNTY MEDICAL CENTER   (United States)

^g ARDIAN Inc   (United States)

Author keywords

hypertension; renin angiotensin system; sympathetic; therapy

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; ALISKIREN; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATRASENTAN; ATROPINE; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; ENDOTHELIN A RECEPTOR; ENZYME INHIBITOR; EPLERENONE; FAD 286; GUANFACINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LCZ 696; LOSARTAN; MEMBRANE METALLOENDOPEPTIDASE; OMAPATRILAT; PLACEBO; RAMIPRIL; RENIN; SPIRONOLACTONE; TELMISARTAN; UNCLASSIFIED DRUG; VALSARTAN;

ADD ON THERAPY; ALBUMINURIA; ANGIONEUROTIC EDEMA; ARTERY DISSECTION; BACKACHE; BLOOD PRESSURE REGULATION; BRADYCARDIA; BREAST TENDERNESS; CARDIOVASCULAR EQUIPMENT; CAROTID BARORECEPTOR STIMULATION DEVICE; CAROTID SINUS PRESSORECEPTOR REFLEX; CATHETER; CATHETER ABLATION; CHRONOTHERAPY; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DEATH; DIZZINESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; EDEMA; ELECTROSTIMULATION; EQUIPMENT DESIGN; EXERCISE; FALSE ANEURYSM; FEMORAL ARTERY; FLUID RETENTION; FLUSHING; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GYNECOMASTIA; HEADACHE; HEART FAILURE; HEART PROTECTION; HEART RATE; HUMAN; HYPERTENSION; HYPOTENSION; IMPLANT; KIDNEY ARTERY STENOSIS; KIDNEY DENERVATION; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; NONHUMAN; PARESTHESIA; PERIPHERAL EDEMA; POSITIVE END EXPIRATORY PRESSURE; POTASSIUM BLOOD LEVEL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SLEEP APNEA SYNDROME; SODIUM RESTRICTION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; WEIGHT REDUCTION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; EQUIPMENT AND SUPPLIES; EQUIPMENT DESIGN; HUMANS; HYPERTENSION;

EID: 79959880590     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.71     Document Type: Review

References (97)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 365(9455), 217-223 (2005) (Pubitemid 40138015)
2. WHO. Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. WHO Press, Geneva, Switzerland (2009)
3. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for Type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N. Engl. J. Med. 342(13), 905-912 (2000) (Pubitemid 30177050)
4. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J. Hypertens. 25(6), 1105-1187 (2007) (Pubitemid 46924065)
5. Perkovic V, Huxley R, Wu Y, Prabhakaran D, Macmahon S. The burden of blood pressure-related disease: a neglected priority for global health. Hypertension 50(6), 991-997 (2007) (Pubitemid 350172916)
6. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J. Hypertens. 22(1), 11-19 (2004) (Pubitemid 38293521)
7. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 290(2), 199-206 (2003) (Pubitemid 37430058)
8. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51(6), 1403-1419 (2008)
9. Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)J. Clin. Hypertens. (Greenwich) 4(6), 393-404 (2002) (Pubitemid 35469393)
10. Pimenta E, Gaddam KK, Oparil S et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 54(3), 475-481 (2009)
11. Graudal NA, Galloe AM, Garred P. Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride: a meta-analysis. JAMA 279(17), 1383-1391 (1998) (Pubitemid 28198806)
12. Ekinci EI, Clarke S, Thomas MC et al. Dietary salt intake and mortality in patients with Type 2 diabetes. Diabetes Care 34(3), 703-709 (2011)
13. Thomas MC, Moran J, Forsblom C et al. The association between dietary sodium intake, ESRD, and all-cause mortality in patients with Type 1 diabetes. Diabetes Care 34(4), 861-866 (2011)
14. Paterna S, Gaspare P, Fasullo S, Sarullo FM, Di Pasquale P. Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend? Clin. Sci. (Lond.) 114(3), 221-230 (2008) (Pubitemid 351293997)
15. Huang Z, Willett WC, Manson JE et al. Body weight, weight change, and risk for hypertension in women. Ann. Intern. Med. 128(2), 81-88 (1998) (Pubitemid 28053128)
16. Cocco G, Pandolfi S. Physical exercise with weight reduction lowers blood pressure and improves abnormal left ventricular relaxation in pharmacologically treated hypertensive patients. J. Clin. Hypertens. (Greenwich) 13(1), 23-29 (2011)
17. Straznicky NE, Grima MT, Eikelis N et al. The effects of weight loss versus weight loss maintenance on sympathetic nervous system activity and metabolic syndrome components. J. Clin. Endocrinol. Metab. 96(3), E503-E508 (2011)
18. Daniels SR, Kimball TR, Khoury P, Witt S, Morrison JA. Correlates of the hemodynamic determinants of blood pressure. Hypertension 28(1), 37-41 (1996) (Pubitemid 26231087)
19. Stamler J. Epidemiologic findings on body mass and blood pressure in adults. Ann. Epidemiol. 1(4), 347-362 (1991)
20. Haynes RB, Mcdonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA 288(22), 2880-2883 (2002) (Pubitemid 35425074)
21. Straznicky N, Grassi G, Esler M et al. European Society of Hypertension Working Group on obesity antihypertensive effects of weight loss: myth or reality? J. Hypertens. 28(4), 637-643 (2010)
22. Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 292(14), 1724-1737 (2004) (Pubitemid 39346675)
23. Maggard MA, Shugarman LR, Suttorp M et al. Meta-analysis: surgical treatment of obesity. Ann. Intern. Med. 142(7), 547-559 (2005)
24. Sjostrom CD, Peltonen M, Sjostrom L. Blood pressure and pulse pressure during long-term weight loss in the obese: the Swedish Obese Subjects (SOS) Intervention Study. Obes. Res. 9(3), 188-195 (2001) (Pubitemid 33600279)
25. Sugerman HJ, Wolfe LG, Sica DA, Clore JN. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann. Surg. 237(6), 751-756; discussion 757-758 (2003).
26. Adami G, Murelli F, Carlini F, Papadia F, Scopinaro N. Long-term effect of biliopancreatic diversion on blood pressure in hypertensive obese patients. Am. J. Hypertens. 18(6), 780-784 (2005) (Pubitemid 40745262)
27. Hermida RC, Ayala DE, Fernandez JR, Calvo C. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension 51(1), 69-76 (2008) (Pubitemid 350307106)
28. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Effects of time of antihypertensive treatment on ambulatory blood pressure and clinical characteristics of subjects with resistant hypertension. Am. J. Hypertens. 23(4), 432-439 (2010)
29. Matos JP, de Lourdes Rodrigues M, Ismerim VL, Boasquevisque EM, Genelhu V, Francischetti EA. Effects of dual blockade of the renin angiotensin system in hypertensive Type 2 diabetic patients with nephropathy. Clin. Nephrol. 64(3), 180-189 (2005) (Pubitemid 41263975)
30. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann. Intern. Med. 148(1), 30-48 (2008) (Pubitemid 351688350)
31. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358(15), 1547-1559 (2008) (Pubitemid 351522739)
32. Tobe SW, Clase CM, Gao P et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 123(10), 1098-1107 (2011)
33. Mcalister FA, Zhang J, Tonelli M, Klarenbach S, Manns BJ, Hemmelgarn BR. The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis. CMAJ 183(6), 655-662 (2011)
34. Maione A, Navaneethan SD, Graziano G et al. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol. Dial. Transplant. DOI: 10.1093/ ndt/gfq792 (2011) (Epub ahead of print)
35. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 39(1), E1-E8 (2002)
36. Stanton A, Jensen C, Nussberger J, O'brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42(6), 1137-1143 (2003) (Pubitemid 37549068)
37. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111(8), 1012-1018 (2005) (Pubitemid 40354519)
38. Duprez DA, Munger MA, Botha J, Keefe DL, Charney AN. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J. Hum. Hypertens. 24(9), 600-608 (2010)
39. Solomon SD, Appelbaum E, Manning WJ et al. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 119(4), 530-537 (2009)
40. Solomon SD, Hee Shin S, Shah A et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur. Heart J. 32(10), 1227-1234 (2011)
41. Seed A, Gardner R, Mcmurray J et al. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur. J. Heart Fail. 9(11), 1120-1127 (2007) (Pubitemid 47633316)
42. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in Type 2 diabetes and nephropathy. N. Engl. J. Med. 358(23), 2433-2446 (2008) (Pubitemid 351793017)
43. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH. Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with Type 2 diabetes and nephropathy. Clin. J. Am. Soc. Nephrol. 6(5),1025-1031 (2011)
44. Brown MJ, Mcinnes GT, Papst CC, Zhang J, Macdonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 377(9762), 312-320 (2011)
45. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359(23), 2417-2428 (2008)
46. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341(10), 709-717 (1999) (Pubitemid 29407370)
47. Chapman N, Dobson J, Wilson S et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49(4), 839-845 (2007) (Pubitemid 351664214)
48. De Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 55(1), 147-152 (2010)
49. Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J. Am. Soc. Hypertens. 2(6), 462-468 (2008)
50. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am. J. Kidney Dis. 37(4), 699-705 (2001) (Pubitemid 32268029)
51. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40(6), 892-896 (2002) (Pubitemid 35434912)
52. Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J Jr. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J. Hum. Hypertens. 17(5), 349-352 (2003) (Pubitemid 36625965)
53. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J. Hypertens. 22(11), 2217-2226 (2004) (Pubitemid 39463817)
54. Calhoun DA. Is there an unrecognized epidemic of primary aldosteronism? Pro. Hypertension 50(3), 447-453; discussion 447-453 (2007)
55. Douma S, Petidis K, Doumas M et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 371(9628), 1921-1926 (2008). (Pubitemid 351778191)
56. Fiebeler A, Nussberger J, Shagdarsuren E et al. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 111(23), 3087-3094 (2005) (Pubitemid 40847786)
57. Menard J, Gonzalez MF, Guyene TT, Bissery A. Investigation of aldosterone-synthase inhibition in rats. J. Hypertens. 24(6), 1147-1155 (2006) (Pubitemid 43772323)
58. + in Wistar rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 295(1), R166-R172 (2008)
59. Mulder P, Mellin V, Favre J et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur. Heart J. 29(17), 2171-2179 (2008)
60. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am. J. Hypertens. 17(2), 103-111 (2004) (Pubitemid 38125125)
61. Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375(9722), 1255-1266 (2010)
62. Nakov R, Pfarr E, Eberle S. Darusentan: an effective endothelin. A receptor antagonist for treatment of hypertension. Am. J. Hypertens. 15(7 Pt 1), 583-589 (2002) (Pubitemid 34734804)
63. Black HR, Bakris GL, Weber MA et al. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J. Clin. Hypertens. (Greenwich) 9(10), 760-769 (2007)
64. Weber MA, Black H, Bakris G et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 374(9699), 1423-1431 (2009)
65. Bakris GL, Lindholm LH, Black HR et al. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension 56(5), 824-830 (2010)
66. Raichlin E, Prasad A, Mathew V et al. Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension 52(3), 522-528 (2008)
67. Kohan DE, Pritchett Y, Molitch M et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J. Am. Soc. Nephrol. 22(4), 763-772 (2011)
68. Nieto FJ, Young TB, Lind BK et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 283(14), 1829-1836 (2000) (Pubitemid 30207619)
69. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N. Engl. J. Med. 342(19), 1378-1384 (2000) (Pubitemid 30262394)
70. Logan AG, Tkacova R, Perlikowski SM et al. Refractory hypertension and sleep apnoea: effect of CPAP on blood pressure and baroreflex. Eur. Respir. J. 21(2), 241-247 (2003) (Pubitemid 36204537)
71. Drager LF, Bortolotto LA, Figueiredo AC, Krieger EM, Lorenzi GF. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am. J. Respir. Crit. Care Med. 176(7), 706-712 (2007) (Pubitemid 47503079)
72. Campos-Rodriguez F, Grilo-Reina A, Perez-Ronchel J et al. Effect of continuous positive airway pressure on ambulatory BP in patients with sleep apnea and hypertension: a placebo-controlled trial. Chest 129(6), 1459-1467 (2006) (Pubitemid 43894973)
73. Becker HF, Jerrentrup A, Ploch T et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 107(1), 68-73 (2003) (Pubitemid 36070935)
74. Drager LF, Pedrosa RP, Diniz PM et al. The effects of continuous positive airway pressure on prehypertension and masked hypertension in men with severe obstructive sleep apnea. Hypertension 57(3), 549-555 (2011)
75. Lohmeier TE, Irwin ED, Rossing MA, Serdar DJ, Kieval RS. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension 43(2), 306-311 (2004) (Pubitemid 38174130)
76. Illig KA, Levy M, Sanchez L et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter Phase II Rheos feasibility trial. J. Vasc. Surg. 44(6), 1213-1218 (2006)
77. Lovett EG, Schafer J, Kaufman CL. Chronic baroreflex activation by the Rheos System: an overview of results from european and North American feasibility studies. Conf. Proc. IEEE Eng. Med. Biol. Soc. 4626-4630 (2009)
78. Sanchez LA, Illig K, Levy M et al. Implantable carotid sinus stimulator for the treatment of resistant hypertension: local effects on carotid artery morphology. Ann. Vasc. Surg. 24(2), 178-184 (2010)
79. Krum H, Schlaich M, Sobotka P, Scheffers I, Kroon AA, De Leeuw PW. Novel procedure- and device-based strategies in the management of systemic hypertension. Eur. Heart J. 32(5), 537-544 (2011)
80. Heusser K, Tank J, Engeli S et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 55(3), 619-626 (2010)
81. Young KC, Teeters JC, Benesch CG, Bisognano JD, Illig KA. Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator. J. Clin. Hypertens. (Greenwich) 11(10), 555-563 (2009)
82. Campese VM. Neurogenic factors and hypertension in chronic renal failure. J. Nephrol. 10(4), 184-187 (1997) (Pubitemid 27333193)
83. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J. Am. Med. Assoc. 152(16), 1501-1504 (1953)
84. Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet 1(6757), 403-408 (1953)
85. Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 54(6), 1195-1201 (2009)
86. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373(9671), 1275-1281 (2009)
87. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N. Engl. J. Med. 361(9), 932-934 (2009).
88. Schlaich MP, Krum H, Sobotka PA, Esler MD. Renal denervation and hypertension. Am. J. Hypertens. 24(6), 635-642(2011)
89. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 57(5), 911-917 (2011)
90. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 50(5), 1641-1650 (1996) (Pubitemid 26364270)
91. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am. J. Kidney Dis. 36(3), 646-661 (2000)
92. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376(9756), 1903-1909 (2010)
93. Lambert GW, Straznicky NE, Lambert EA, Dixon JB, Schlaich MP. Sympathetic nervous activation in obesity and the metabolic syndrome - causes, consequences and therapeutic implications. Pharmacol. Ther. 126(2), 159-172 (2010)
94. Mahfoud F, Schlaich M, Kindermann I et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study Circulation 123(1), 1940-1946 (2011)
95. Schlaich MP, Straznicky N, Grima M et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J. Hypertens. 29(5), 991-996 (2011)
96. Schlaich MP, Socratous F, Hennebry S et al. Sympathetic activation in chronic renal failure. J. Am. Soc. Nephrol. 20(5), 933-939 (2009)
97. Straznicky NE, Grima MT, Lambert EA et al. Exercise augments weight loss induced improvement in renal function in obese metabolic syndrome individuals. J. Hypertens. 29(3), 553-564 (2011).